The new B7s: Playing a pivotal role in tumor immunity

被引：160

作者：

Flies, Dallas B.

Chen, Lieping

机构：

[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

[2] Johns Hopkins Univ, Sch Med, Grad Program Immunol, Baltimore, MD 21231 USA

来源：

JOURNAL OF IMMUNOTHERAPY | 2007年 / 30卷 / 03期

关键词：

tumor immunity; immunotherapy; B7-H1; B7-DC; B7-H2; B7-H3; B7-H4; RENAL-CELL CARCINOMA; INDUCIBLE COSTIMULATOR LIGAND; PROGRAMMED DEATH-1 LIGAND-1; CROSS-LINKING ANTIBODY; T-CELLS; POTENTIAL MECHANISM; B7-H4; EXPRESSION; INTERFERON-GAMMA; EPITHELIAL-CELLS; FAMILY-MEMBER;

D O I：

10.1097/CJI.0b013e31802e085a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B7-H1, B7-DC, B7-H2, B7-H3, and B7-H4, all new additions to the B7 family.. here termed "the, new B7s" are emerging as important tools in directing immune function; each with unique.. yet often overlapping functions. Clearly, each B7 molecule has developed its own indispensable niche in the immune system. The expression of both stimulatory and inhibitory B7 molecules seems to play an essential role in regulating the immune response to transformed cells through a variety of mechanisms. As specific niches of B7 family members continue to be dissected, their diagnostic and therapeutic potential becomes ever more apparent. In this review, we will discuss the role of the new B7s in activation and inhibition of antitumor immune responses., their prospects in diagnostics, and also potential and developing immunotherapy protocols.

引用

收藏

页码：251 / 260

页数：10

相关论文

共 119 条

[1] The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].

Ansari, MJI ;

Salama, AD ;

Chitnis, T ;

Smith, RN ;

Yagita, H ;

Akiba, H ;

Yamazaki, T ;

Azuma, M ;

Iwai, H ;

Khoury, SJ ;

Auchincloss, H ;

Sayegh, MH .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69

[2] Current developments of immunotherapy in the clinic [J].

Antonia, S ;

Mulé, JJ ;

Weber, JS .

CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (02) :130-136

[3] Restoring function in exhausted CD8 T cells during chronic viral infection [J].

Barber, DL ;

Wherry, EJ ;

Masopust, D ;

Zhu, BG ;

Allison, JP ;

Sharpe, AH ;

Freeman, GJ ;

Ahmed, R .

NATURE, 2006, 439 (7077) :682-687

[4] Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro [J].

Blank, C ;

Kuball, J ;

Voelkl, S ;

Wiendl, H ;

Becker, B ;

Walter, B ;

Majdic, O ;

Gajewski, TF ;

Theobald, M ;

Andreesen, R ;

Mackensen, A .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) :317-327

[5] Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy [J].

Blank, C ;

Gajewski, TF ;

Mackensen, A .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) :307-314

[6] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].

Blank, C ;

Brown, I ;

Peterson, AC ;

Spiotto, M ;

Iwai, Y ;

Honjo, T ;

Gajewski, TF .

CANCER RESEARCH, 2004, 64 (03) :1140-1145

[7] Monoclonal and bispecific antibodies as novel therapeutics [J].

Booy, EP ;

Johar, D ;

Maddika, S ;

Pirzada, H ;

Sahib, MM ;

Gehrke, I ;

Loewen, S ;

Louis, SF ;

Kadkhoda, K ;

Mowat, M ;

Los, M .

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2006, 54 (02) :85-101

[8] A THEORY OF SELF-NONSELF DISCRIMINATION [J].

BRETSCHER, P ;

COHN, M .

SCIENCE, 1970, 169 (3950) :1042-+

[9] LICOS, a primordial costimulatory ligand? [J].

Brodie, D ;

Collins, AV ;

Iaboni, A ;

Fennelly, JA ;

Sparks, LM ;

Xu, XN ;

van der Merwe, PA ;

Davis, SJ .

CURRENT BIOLOGY, 2000, 10 (06) :333-336

[10] Therapeutic opportunities in the B7/CD28 family of ligands and receptors [J].

Carreno, BM ;

Carter, LL ;

Collins, M .

CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (04) :424-430

← 1 2 3 4 5 6 7 8 9 10 →